» Articles » PMID: 29389929

Disease Recurrence Following Surgery for Colorectal Cancer: Five-year Follow-up

Overview
Journal N Z Med J
Specialty General Medicine
Date 2018 Feb 2
PMID 29389929
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To describe the patterns of recurrence in a contemporaneous cohort of patients undergoing surgery with curative intent for colorectal adenocarcinoma at a New Zealand hospital with five-year follow-up.

Methods: Patients with colorectal cancer undergoing potentially curative surgery between January 2010 and December 2012 were followed up for a median of 61 months with three-monthly CEA (carcinoembryonic antigen), a colonoscopy after one year and yearly computed tomography scans of the chest, abdomen and pelvis for the first three years.

Results: Overall, 59/237 (24.9%) of patients experienced disease recurrence, the most common sites being the liver, followed by the lung and local recurrence. Recurrence rates did not differ significantly between colon and rectal cancer and ranged from 5.1% in stage I to 60% in stage IV. Seventy-three percent of all recurrences were observed within the first 24 months post-operatively.

Conclusion: While New Zealand outcomes in colorectal cancer have historically compared unfavourably against international standards, the outcomes observed in this cohort are encouraging and may reflect advances in care, including multidisciplinary team discussion, increased use of adjuvant therapy, surgical subspecialisation and protocolled surveillance and follow-up.

Citing Articles

Prediction of the survival status and tumor microenvironment in colorectal cancer through genotyping analysis based on toll-like receptors.

Peng H, Zhang J, Yang Z, Chen L, Chen J, Cai C Saudi J Gastroenterol. 2024; 30(4):243-251.

PMID: 38813725 PMC: 11379252. DOI: 10.4103/sjg.sjg_424_23.


Cumulative Incidence, Risk Factors, and Overall Survival of Disease Recurrence after Curative Resection of Stage II-III Colorectal Cancer: A Population-based Study.

Boute T, Swartjes H, Greuter M, Elferink M, van Eekelen R, Vink G Cancer Res Commun. 2024; 4(2):607-616.

PMID: 38363145 PMC: 10903299. DOI: 10.1158/2767-9764.CRC-23-0512.


Recurrence and Postoperative Death in Patients with Colorectal Cancer: A New Perspective via Semi-competing Risk Framework.

Safari M, Mahmoudi L, Baker E, Roshanaei G, Fallah R, Shahnavaz A Turk J Gastroenterol. 2023; 34(7):736-746.

PMID: 37232463 PMC: 10441135. DOI: 10.5152/tjg.2023.22540.


Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H JAMA. 2023; 329(15):1271-1282.

PMID: 37071094 PMC: 10114040. DOI: 10.1001/jama.2023.4428.


Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in China.

Ren Y, Zhao M, Zhou D, Xing Q, Gong F, Tang W Front Public Health. 2022; 10:952378.

PMID: 36033786 PMC: 9412186. DOI: 10.3389/fpubh.2022.952378.